PALVELLA THERAPEUTICS, INC. 8-K

What Happened

• Palvella Therapeutics, Inc. announced on July 14, 2026 that it posted a corporate presentation to its website. The presentation was filed with the SEC as Exhibit 99.1 and will be used by company representatives in meetings with investors.
• The 8-K reporting this event was signed by Matthew Korenberg, Chief Financial Officer, and incorporated the presentation by reference.

Key Details

• Date posted and filed: July 14, 2026.
• Exhibit: Corporate Presentation filed as Exhibit 99.1 to the Form 8-K.
• Purpose: Presentation to be used in various investor meetings (per company statement).
• SEC filing sections: Item 8.01 (Other Events) and Item 9.01 (Exhibits).

Why It Matters

• The filing indicates Palvella is actively communicating with investors and has made updated corporate materials publicly available.
• Investors should review the posted presentation (Exhibit 99.1) for any information on the company’s strategy, programs, timeline, or financial outlook that could affect investment decisions.
• No financial results, mergers, or executive changes were reported in this 8-K; the filing solely documents the posting of the investor presentation.